HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) and Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), today jointly announce that the FRUSICA-2 Phase II/III clinical trial...Read more
First US Phase 3 study of Photodynamic Therapy (PDT) to include neck, trunk and extremities Protocol involves one or two PDT treatments using 1-3 tubes of Ameluz® or vehicle gel over a surface area of up to 240 cm2 Treatment phase expected to be complete by Q3 2025 WOBURN,...Read more
New Data Demonstrates Significant Reduction in Tumor Growth and KIT Expression in Preclinical GIST Models Induction of Tumor Cell Death – HT-KIT triggered significant tumor cell death as early as 24 hours post-treatment, while the lower dose led to delayed but substantial...Read more
Sjögren's disease (SjD) is a prevalent, debilitating autoantibody disease with no FDA-approved advanced treatments The Company is actively enrolling patients in the Phase 3 DAFFODIL study This marks the fourth nipocalimab FDA Fast Track designation SPRING...Read more
HYDERABAD, India and REYKJAVIK, Iceland, March 18, 2025 (GLOBE NEWSWIRE) -- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “Dr. Reddy’s”) and Alvotech (NASDAQ: ALVO), a global biotech company specializing...Read more
TAMPA, FL, March 18, 2025 (GLOBE NEWSWIRE) -- – SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and...Read more
Assertio is a leading commercial pharmaceutical company bringing differentiated products to patients. The Company has a robust portfolio of branded prescription products in three areas: neurology, hospital, and pain and inflammation. Assertio has grown through...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Regencell Bioscience | 10.80 58.38 | $29.30 |
| AbbVie | 9.77 4.79 | $213.85 |
| Mettler-Toledo | 7.71 0.62 | $1,242.73 |
| McKesson | 6.36 0.97 | $661.61 |
| Elevance Health | 5.66 1.31 | $436.25 |
| Cigna | 5.63 1.78 | $322.43 |
| Humana | 5.37 2.03 | $269.78 |
| UnitedHealth | 4.78 0.96 | $503.80 |
| Tonix Pharmaceuticals | 4.36 26.78 | $20.64 |
| Becton Dickinson | 4.29 1.88 | $232.12 |
| Harrow | 3.66 15.69 | $26.98 |
| IQVIA | 3.64 1.97 | $188.54 |
| Waters | 3.23 0.85 | $382.15 |
| Aditxt | 3.05 69.79 | $7.42 |
| Bio-Rad Laboratories | 3.03 1.18 | $260.03 |
| West Pharmaceutical | 3.01 1.30 | $234.47 |
| Stryker | 2.42 0.65 | $375.91 |
| Arcellx | 2.29 3.39 | $69.87 |
| Company | Volume | Last Trade |
|---|---|---|
| Syros Pharmaceuticals | 394,617,118 | $0.13 |
| Aditxt | 90,261,997 | $7.42 |
| Scienture | 62,264,623 | $1.59 |
| Genprex | 43,333,432 | $0.34 |
| Pfizer | 31,705,791 | $26.31 |
| Vincerx Pharma | 24,111,011 | $0.72 |
| Indaptus Therapeutics | 17,895,682 | $0.81 |
| Recursion | 17,609,294 | $6.39 |
| Quantum-Si | 16,593,638 | $1.58 |
| Viatris | 13,926,008 | $9.52 |
| Sarepta Therapeutics | 13,338,295 | $73.18 |
| Senseonics | 13,085,180 | $0.60 |
| Sangamo Therapeutics | 11,695,001 | $0.85 |
| CVS Health | 10,637,796 | $67.57 |
| Sana Biotechnology | 10,566,041 | $2.28 |
| Ocean Biomedical | 10,154,585 | $0.06 |
| Virpax Pharmaceuticals | 9,627,793 | $0.13 |
| Tempus AI | 9,592,045 | $45.86 |
| Bristol-Myers Squibb | 9,585,268 | $59.90 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including a small-molecule GLP-1 receptor...
CLICK TO LEARN MORE
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking’s research and development activities leverage...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
